The main purpose of this research, in collaboration with Dafra Pharma R&D within a Baekeland-funded IWT project, is to develop innovative, patentable formulations resulting in an increased stability and a modified biopharmaceutical profile of the 1,2,4-trioxane derivatives, which meets more the clinical needs, in casu a decreased pharmacokinetic variability and a modified release profile. Polymers will be examined as excipients in their processability with hot-melt extrusion as the preferred manufacturing method for the production of tablets, development of a transdermal system and an implent (e.g. IUD) for several medical applications.